ORKA Quote, Financials, Valuation and Earnings

LifeMD has a net margin of -- compared to Oruka Therapeutics's net margin of -9.61%. Oruka Therapeutics's return on equity of -- beat LifeMD's return on equity of --.

Oruka Therapeutics has a consensus price target of $43.17, signalling upside risk potential of 112.75%. On the other hand LifeMD has an analysts' consensus of $12.00 which suggests that it could grow by 138.1%. Given that LifeMD has higher upside potential than Oruka Therapeutics, analysts believe LifeMD is more attractive than Oruka Therapeutics.

Oruka Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LifeMD has a beta of 1.376, suggesting its more volatile than the S&P 500 by 37.561%.

Oruka Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LifeMD offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oruka Therapeutics pays -- of its earnings as a dividend. LifeMD pays out -15.08% of its earnings as a dividend.

Oruka Therapeutics quarterly revenues are --, which are smaller than LifeMD quarterly revenues of $53.4M. Oruka Therapeutics's net income of -$28.6M is lower than LifeMD's net income of -$5.1M. Notably, Oruka Therapeutics's price-to-earnings ratio is -- while LifeMD's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oruka Therapeutics is -- versus 1.04x for LifeMD. Usually stocks with elevated PS ratios are considered overvalued.

PetMed Express has a net margin of -- compared to Oruka Therapeutics's net margin of 3.91%. Oruka Therapeutics's return on equity of -- beat PetMed Express's return on equity of -0.96%.

Oruka Therapeutics has a consensus price target of $43.17, signalling upside risk potential of 112.75%. On the other hand PetMed Express has an analysts' consensus of -- which suggests that it could fall by -24.55%. Given that Oruka Therapeutics has higher upside potential than PetMed Express, analysts believe Oruka Therapeutics is more attractive than PetMed Express.

Oruka Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PetMed Express has a beta of 0.711, suggesting its less volatile than the S&P 500 by 28.869%.

Oruka Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PetMed Express offers a yield of 0% to investors and pays a quarterly dividend of $0.30 per share. Oruka Therapeutics pays -- of its earnings as a dividend. PetMed Express pays out -166.63% of its earnings as a dividend.

Oruka Therapeutics quarterly revenues are --, which are smaller than PetMed Express quarterly revenues of $59.6M. Oruka Therapeutics's net income of -$28.6M is lower than PetMed Express's net income of $2.3M. Notably, Oruka Therapeutics's price-to-earnings ratio is -- while PetMed Express's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oruka Therapeutics is -- versus 0.40x for PetMed Express. Usually stocks with elevated PS ratios are considered overvalued.

Streamline Health Solutions has a net margin of -- compared to Oruka Therapeutics's net margin of -56.03%. Oruka Therapeutics's return on equity of -- beat Streamline Health Solutions's return on equity of -54.79%.

Oruka Therapeutics has a consensus price target of $43.17, signalling upside risk potential of 112.75%. On the other hand Streamline Health Solutions has an analysts' consensus of -- which suggests that it could fall by -56.9%. Given that Oruka Therapeutics has higher upside potential than Streamline Health Solutions, analysts believe Oruka Therapeutics is more attractive than Streamline Health Solutions.

Oruka Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Streamline Health Solutions has a beta of 1.675, suggesting its more volatile than the S&P 500 by 67.477%.

Oruka Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Streamline Health Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oruka Therapeutics pays -- of its earnings as a dividend. Streamline Health Solutions pays out -- of its earnings as a dividend.

Oruka Therapeutics quarterly revenues are --, which are smaller than Streamline Health Solutions quarterly revenues of $4.4M. Oruka Therapeutics's net income of -$28.6M is lower than Streamline Health Solutions's net income of -$2.5M. Notably, Oruka Therapeutics's price-to-earnings ratio is -- while Streamline Health Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oruka Therapeutics is -- versus 0.74x for Streamline Health Solutions. Usually stocks with elevated PS ratios are considered overvalued.

TruBridge has a net margin of -- compared to Oruka Therapeutics's net margin of -11.7%. Oruka Therapeutics's return on equity of -- beat TruBridge's return on equity of -31.4%.

Oruka Therapeutics has a consensus price target of $43.17, signalling upside risk potential of 112.75%. On the other hand TruBridge has an analysts' consensus of $12.20 which suggests that it could fall by -12.38%. Given that Oruka Therapeutics has higher upside potential than TruBridge, analysts believe Oruka Therapeutics is more attractive than TruBridge.

Oruka Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison TruBridge has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.832%.

Oruka Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TruBridge offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oruka Therapeutics pays -- of its earnings as a dividend. TruBridge pays out -- of its earnings as a dividend.

Oruka Therapeutics quarterly revenues are --, which are smaller than TruBridge quarterly revenues of $83.8M. Oruka Therapeutics's net income of -$28.6M is lower than TruBridge's net income of -$9.8M. Notably, Oruka Therapeutics's price-to-earnings ratio is -- while TruBridge's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oruka Therapeutics is -- versus 0.77x for TruBridge. Usually stocks with elevated PS ratios are considered overvalued.